Royalty Pharma (RPRX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$56.93
+1.3% on the day
+60.6% over 12 months
52-week range $34.77 – $63.96
Share price and insider trades
RPRX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$92.8M
Insiders buying0
Insiders selling5
Royalty Pharma insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $92.8M of RPRX stock on the open market.
Get emailed when insiders cluster-buy stocks like RPRX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
RPRX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $236K | 1 |
| Q3 2026 | — | 0 | $13.2M | 7 |
| Q2 2026 | — | 0 | $24.5M | 15 |
| Q1 2026 | — | 0 | $24.6M | 23 |
| Q4 2025 | — | 0 | $30.3M | 28 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Royalty Pharma plc insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $92.8M. 74 of 74 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 5SEC | Marshall UristEvp, Research & Investments | Sell Plan | 4,126 | $57.10 | $236K | -0.3% | — |
| Sep 30SEC | Marshall UristEvp, Research & Investments | Sell Plan | 4,1264,126 held (−50%) | $57.88 | $239K | -1.6% | — |
| Sep 24SEC | Christopher HiteChair | Sell Plan | 96,073274,328 held (−26%) | $58.51 | $5.6M | -2.7% | — |
| Sep 24SEC | Christopher HiteChair | Sell Plan | 3,927270,401 held (−1%) | $58.93 | $231K | -3.4% | — |
| Aug 19SEC | Christopher HiteChair | Sell Plan | 100,000370,401 held (−21%) | $59.97 | $6.0M | -5.1% | — |
| Aug 17SEC | Terrance P. CoyneCFO | Sell Plan | 9,2301,772 held (−84%) | $58.59 | $541K | -2.8% | — |
| Aug 17SEC | Terrance P. CoyneCFO | Sell Plan | 1,772 | $59.14 | $105K | -3.7% | — |
| Jul 2SEC | Christopher HiteChair | Sell Plan | 97,446461,953 held (−17%) | $56.50 | $5.5M | +0.8% | — |
| Jul 2SEC | Christopher HiteChair | Sell Plan | 29,40040,600 held (−42%) | $56.44 | $1.7M | +0.9% | — |
| Jul 2SEC | Marshall UristEvp, Research & Investments | Sell Plan | 9,099 | $55.88 | $508K | +1.9% | — |
| Jul 2SEC | Christopher HiteChair | Sell Plan | 2,554459,399 held (−1%) | $57.10 | $146K | -0.3% | — |
| Jul 2SEC | Christopher HiteChair | Sell Plan | 60040,000 held (−1%) | $57.09 | $34K | -0.3% | — |
| Jun 25SEC | Christopher HiteChair | Sell Plan | 117,592559,399 held (−17%) | $54.47 | $6.4M | +4.5% | — |
| Jun 25SEC | Christopher HiteChair | Sell Plan | 32,408676,991 held (−5%) | $54.11 | $1.8M | +5.2% | — |
| Jun 25SEC | Marshall UristEvp, Research & Investments | Sell Plan | 9,0989,099 held (−50%) | $55.18 | $502K | +3.2% | — |
| May 28SEC | Terrance P. CoyneCFO | Sell Plan | 64,399 | $53.98 | $3.5M | +5.5% | — |
| May 21SEC | Marshall UristEvp, Research & Investments | Sell Plan | 13,68418,197 held (−43%) | $52.75 | $722K | +7.9% | — |
| May 15SEC | Marshall UristEvp, Research & Investments | Sell Plan | 13,68431,881 held (−30%) | $53.06 | $726K | +7.3% | — |
| May 15SEC | Gregory NordenDirector | Sell Plan | 3,045191,803 held (−2%) | $53.00 | $161K | +7.4% | — |
| Apr 30SEC | Terrance P. CoyneCFO | Sell Plan | 32,916 | $49.78 | $1.6M | +14.4% | — |
| Apr 30SEC | Terrance P. CoyneCFO | Sell Plan | 1,87540,136 held (−4%) | $49.78 | $93K | +14.4% | — |
| Apr 2SEC | Terrance P. CoyneCFO | Sell Plan | 32,91632,916 held (−50%) | $48.33 | $1.6M | +17.8% | — |
| Apr 2SEC | Terrance P. CoyneCFO | Sell Plan | 1,87542,011 held (−4%) | $48.33 | $91K | +17.8% | — |
| Mar 25SEC | Terrance P. CoyneCFO | Sell Plan | 32,91665,832 held (−33%) | $45.53 | $1.5M | +25.0% | — |
| Mar 25SEC | Terrance P. CoyneCFO | Sell Plan | 1,87543,886 held (−4%) | $45.53 | $85K | +25.0% | — |
| Mar 4SEC | Terrance P. CoyneCFO | Sell Plan | 22,487109,177 held (−17%) | $46.67 | $1.0M | +22.0% | — |
| Mar 4SEC | Terrance P. CoyneCFO | Sell Plan | 10,42998,748 held (−10%) | $47.01 | $490K | +21.1% | — |
| Mar 4SEC | Terrance P. CoyneCFO | Sell Plan | 1,29246,344 held (−3%) | $46.67 | $60K | +22.0% | — |
| Mar 4SEC | Terrance P. CoyneCFO | Sell Plan | 58345,761 held (−1%) | $47.01 | $27K | +21.1% | — |
| Feb 25SEC | Terrance P. CoyneCFO | Sell Plan | 32,916131,664 held (−20%) | $45.32 | $1.5M | +25.6% | — |
| Feb 25SEC | Terrance P. CoyneCFO | Sell Plan | 1,87547,636 held (−4%) | $45.32 | $85K | +25.6% | — |
| Feb 4SEC | Terrance P. CoyneCFO | Sell Plan | 108,759183,656 held (−37%) | $42.84 | $4.7M | +32.9% | — |
| Feb 4SEC | Terrance P. CoyneCFO | Sell Plan | 102,581292,415 held (−26%) | $42.08 | $4.3M | +35.3% | — |
| Feb 4SEC | Terrance P. CoyneCFO | Sell Plan | 19,076164,580 held (−10%) | $43.29 | $826K | +31.5% | — |
| Feb 4SEC | Terrance P. CoyneCFO | Sell Plan | 6,19523,972 held (−21%) | $42.84 | $265K | +32.9% | — |
| Feb 4SEC | Terrance P. CoyneCFO | Sell Plan | 5,84330,167 held (−16%) | $42.08 | $246K | +35.3% | — |
| Feb 4SEC | Terrance P. CoyneCFO | Sell Plan | 1,08722,885 held (−5%) | $43.29 | $47K | +31.5% | — |
| Feb 2SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,000 | $41.09 | $822K | +38.5% | — |
| Jan 26SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,00020,000 held (−50%) | $40.26 | $805K | +41.4% | — |
| Jan 23SEC | Terrance P. CoyneCFO | Sell Plan | 65,832394,996 held (−14%) | $39.35 | $2.6M | +44.7% | — |
| Jan 23SEC | Terrance P. CoyneCFO | Sell Plan | 3,75036,010 held (−9%) | $39.35 | $148K | +44.7% | — |
| Jan 20SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,00040,000 held (−33%) | $39.52 | $790K | +44.1% | — |
| Jan 13SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,00060,000 held (−25%) | $40.78 | $816K | +39.6% | — |
| Jan 6SEC | Terrance P. CoyneCFO | Sell Plan | 65,832460,828 held (−12%) | $38.42 | $2.5M | +48.2% | — |
| Jan 6SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,00080,000 held (−20%) | $38.48 | $770K | +47.9% | — |
| Jan 6SEC | Terrance P. CoyneCFO | Sell Plan | 3,75039,760 held (−9%) | $38.42 | $144K | +48.2% | — |
| Dec 29SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,000100,000 held (−17%) | $39.32 | $786K | +44.8% | — |
| Dec 22SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,000120,000 held (−14%) | $38.38 | $768K | +48.3% | — |
| Dec 19SEC | George W. LloydGeneral Counsel | Sell Plan | 79,34630,654 held (−72%) | $38.57 | $3.1M | +47.6% | — |
| Dec 19SEC | George W. LloydGeneral Counsel | Sell Plan | 30,654 | $38.50 | $1.2M | +47.9% | — |
| Dec 17SEC | Terrance P. CoyneCFO | Sell Plan | 65,832526,660 held (−11%) | $38.36 | $2.5M | +48.4% | — |
| Dec 17SEC | Marshall UristEvp, Research & Investments | Sell Plan | 20,000140,000 held (−12%) | $38.32 | $766K | +48.6% | — |
| Dec 17SEC | Terrance P. CoyneCFO | Sell Plan | 3,75043,510 held (−8%) | $38.36 | $144K | +48.4% | — |
| Dec 9SEC | Marshall UristEvp, Research & Investments | Sell Plan | 23,334160,000 held (−13%) | $39.15 | $914K | +45.4% | — |
| Dec 9SEC | Marshall UristEvp, Research & Investments | Sell Plan | 18,2427,398 held (−71%) | $39.15 | $714K | +45.4% | — |
| Dec 5SEC | George W. LloydGeneral Counsel | Sell Plan | 110,000110,000 held (−50%) | $39.77 | $4.4M | +43.1% | — |
| Dec 3SEC | Terrance P. CoyneCFO | Sell Plan | 65,832592,492 held (−10%) | $39.87 | $2.6M | +42.8% | — |
| Dec 3SEC | Marshall UristEvp, Research & Investments | Sell Plan | 23,333183,334 held (−11%) | $39.93 | $932K | +42.6% | — |
| Dec 3SEC | Marshall UristEvp, Research & Investments | Sell Plan | 18,24225,640 held (−42%) | $39.90 | $728K | +42.7% | — |
| Dec 3SEC | Terrance P. CoyneCFO | Sell Plan | 3,75047,260 held (−7%) | $39.87 | $150K | +42.8% | — |
| Nov 26SEC | Terrance P. CoyneCFO | Sell Plan | 55,146669,010 held (−8%) | $38.67 | $2.1M | +47.2% | — |
| Nov 26SEC | Terrance P. CoyneCFO | Sell Plan | 10,686658,324 held (−2%) | $37.96 | $406K | +50.0% | — |
| Nov 26SEC | Terrance P. CoyneCFO | Sell Plan | 3,12651,634 held (−6%) | $38.67 | $121K | +47.2% | — |
| Nov 26SEC | Terrance P. CoyneCFO | Sell Plan | 62451,010 held (−1%) | $37.96 | $24K | +50.0% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 47,79810,712 held (−82%) | $38.28 | $1.8M | +48.7% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 47,4014,599 held (−91%) | $38.28 | $1.8M | +48.7% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 25,5302,470 held (−91%) | $38.28 | $977K | +48.7% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 4,6286,084 held (−43%) | $39.01 | $181K | +45.9% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 4,599 | $39.01 | $179K | +45.9% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 2,770230 held (−92%) | $38.29 | $106K | +48.7% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 2,470 | $39.01 | $96K | +45.9% | — |
| Nov 21SEC | George W. LloydGeneral Counsel | Sell Plan | 230 | $39.03 | $9K | +45.9% | — |
| Nov 19SEC | Terrance P. CoyneCFO | Sell Plan | 65,844724,156 held (−8%) | $39.30 | $2.6M | +44.9% | — |
| Nov 19SEC | Terrance P. CoyneCFO | Sell Plan | 3,75054,760 held (−6%) | $39.30 | $147K | +44.9% | — |
Insiders at Royalty Pharma plc
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Terrance P. CoyneCFO | — | $39.0M | Aug 17, 2026 | — |
| Christopher HiteChair | — | $27.4M | Sep 24, 2026 | — |
| George W. LloydGeneral Counsel | — | $13.8M | Dec 19, 2025 | — |
| Marshall UristEvp, Research & Investments | — | $12.5M | Oct 5, 2026 | — |
| Gregory NordenDirector | — | $161K | May 15, 2026 | — |
RPRX stock: common questions
Are Royalty Pharma plc insiders buying RPRX stock?
In the past 12 months, 0 insiders reported open-market purchases of RPRX worth $0.
Are Royalty Pharma plc insiders selling RPRX stock?
5 insiders reported sales worth $92.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RPRX's 52-week range?
Over the past year RPRX has traded between $34.77 and $63.96. It last closed at $56.93 on Oct 9, 2026.